La Jolla Pharmaceutical Company
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$6.4M
Doctors Paid
8,547
Transactions
18,917
2024 Total
$705,902
Payment Breakdown by Category
Research$2.5M (38.6%)
Food & Beverage$730,569 (11.4%)
Consulting$247,937 (3.9%)
Travel$189,516 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.5M | 350 | 38.6% |
| Honoraria | $1.5M | 559 | 23.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 352 | 18.0% |
| Food and Beverage | $730,569 | 16,591 | 11.4% |
| Consulting Fee | $247,937 | 106 | 3.9% |
| Travel and Lodging | $189,516 | 677 | 3.0% |
| Space rental or facility fees (teaching hospital only) | $81,980 | 69 | 1.3% |
| Education | $33,362 | 211 | 0.5% |
| Grant | $20,000 | 2 | 0.3% |
Payments by Type
General
$3.9M
18,567 transactions
Research
$2.5M
350 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 2, MULTI-CENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY WITH LJPC-401 FOR THE TREATMENT OF IRON OVERLOAD IN ADULT PATIENTS WITH HEREDITARY HEMOCHROMATOSIS | $1.3M | 0 | 267 |
| A Multi-Center, Randomized, Open-Label, Parallel Group Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia | $419,361 | 0 | 4 |
| A MULTI-CENTER, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY WITH LJPC-401 FOR THE TREATMENT OF MYOCARDIAL IRON OVERLOAD IN ADULT PATIENTS WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA | $147,341 | 0 | 25 |
| A National Surveillance Program to Evaluate the In Vitro Potency of Standard-of-Care Antibiotics against Contemporary Acinetobacter baumannii-calcoaceticus complex isolates acquired from Hospitalized Patients | $129,100 | 0 | 4 |
| A STUDY OF LJPC-501 IN PEDIATRIC PATIENTS WITH HYPOTENSION | $102,103 | 0 | 10 |
| Angiotensin-II in Sepsis: Immune scRNA Seq Proposal Summary | $99,000 | 0 | 1 |
| EXPANDED ACCESS FOR LJPC-501 | $55,592 | 0 | 16 |
| Ex vivo modeling and simulation to guide Sulbactum Durlobactam dosing | $39,875 | 0 | 2 |
| Development and validation for the measurement of sulbactam and durlobactam in plasma free filtrate (PFF), effluent, and plasma via LC-MS/MS | $30,000 | 0 | 1 |
| Y site compatibility with sulbactam-durlobactam | $25,884 | 0 | 1 |
| Physical Compatibility with Sulbactam Durlobactam | $25,883 | 0 | 1 |
| In vitro static time kills with cefepime | $23,518 | 0 | 2 |
| EFFECT OF CARDIOPULMONARY BYPASS ON SERUM BIOMARKERS OF IRON | $16,296 | 0 | 7 |
| Angiotensin II as a first-line vasopressor for distributive shock for heart transplant and left ventricular assist device implantation recipients: A Pilot Study | $13,257 | 0 | 1 |
| The Effect of Angiotensin II on Vasoplegic Shock | $12,617 | 0 | 1 |
| Medication Use Evaluation with GIAPREZA for Patients with distributive shock including COVID-19 | $9,996 | 0 | 4 |
| Angiotensin II in Liver Transplantation (ANGLT-1): A Pilot Randomized Controlled Trial | $7,116 | 0 | 1 |
| DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) pilot: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock, a randomized controlled pilot trial | $1,920 | 0 | 1 |
| A Phase 2, Multi-Center, Randomized, Placebo Controlled, Double-Blind Study With LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis | $909.70 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Ara Klijian, M.d, M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | San Diego, CA | $446,781 | $0 |
| Jonathan Chow, M.d, M.D | Critical Care Medicine | Washington, DC | $243,653 | $0 |
| Dr. Michael Gelfand, Md, MD | Infectious Disease | Memphis, TN | $140,849 | $0 |
| David Boldt, M.d, M.D | Critical Care Medicine | Los Angeles, CA | $132,474 | $0 |
| Bruce Friedman, M.d, M.D | Critical Care Medicine | Augusta, GA | $122,910 | $0 |
| Louis Guzzi, Md, MD | Critical Care Medicine | Orlando, FL | $90,863 | $0 |
| Dr. Christian Sandrock, Md, MD | Internal Medicine | Sacramento, CA | $88,639 | $0 |
| Harold Szerlip, Md, MD | Internal Medicine | Charleston, SC | $83,116 | $0 |
| Dr. David Willms, M.d, M.D | Pulmonary Disease | San Diego, CA | $72,071 | $0 |
| Dr. Fariborz Rezai, M.d, M.D | Internal Medicine | Livingston, NJ | $62,428 | $0 |
| Dr. Ashish Khanna, M.d, M.D | Critical Care Medicine | Winston Salem, NC | $61,767 | $0 |
| Dr. Juan Diaz, D.o, D.O | Infectious Disease | Altamonte Springs, FL | $60,688 | $0 |
| Dr. Laurence Busse, M.d, M.D | Internal Medicine | Washington, DC | $58,378 | $0 |
| Dr. Michael Seneff, Md, MD | Internal Medicine | Washington, DC | $55,310 | $0 |
| Rajkumar Dasgupta, M.d, M.D | Pulmonary Disease | Pasadena, CA | $54,545 | $0 |
| Shravan Kethireddy, M.d, M.D | Infectious Disease | Madison, WI | $44,715 | $0 |
| Dr. Jeffery Vender, Md, MD | Anesthesiology | Evanston, IL | $41,194 | $0 |
| Samir Awad, Md, MD | Surgery | Houston, TX | $41,079 | $0 |
| Dr. Timothy Misselbeck, Md, MD | Surgery | Allentown, PA | $40,400 | $0 |
| Dr. Christopher Junker, Md, MD | Anesthesiology | Washington, DC | $39,604 | $0 |
| Laurie Grier, M.d, M.D | Internal Medicine | Shreveport, LA | $38,300 | $0 |
| Mr. Tony Hodges, M.d, M.D | Pulmonary Disease | Phoenix, AZ | $30,774 | $0 |
| Dr. Joshua Martin, Dnp-Np/C, DNP-NP/C | Nurse Practitioner | Petoskey, MI | $29,932 | $0 |
| Nishant Patel, Md, MD | Surgery | Palm Beach Gardens, FL | $29,694 | $0 |
| Dr. Joshua Rosenberg, M.d, M.D | Critical Care Medicine | Brooklyn, NY | $29,233 | $0 |
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company has made $6.4M in payments to 8,547 healthcare providers, recorded across 18,917 transactions in the CMS Open Payments database. In 2024, the company paid $705,902. The top product by payment volume is GIAPREZA ($3.9M).
Payments were distributed across 138 medical specialties. The top specialty by payment amount is Critical Care Medicine ($900,051 to 661 doctors).
Payment categories include: Food & Beverage ($730,569), Consulting ($247,937), Research ($2.5M), Travel & Lodging ($189,516).
La Jolla Pharmaceutical Company is associated with 3 products in the CMS Open Payments database.